home / stock / supn / supn articles

SUPN Articles, Supernus Pharmaceuticals Inc. - From 05/09/24

Stock Information
Company Name: Supernus Pharmaceuticals Inc.
Stock Symbol: SUPN
Market: NASDAQ
Website: supernus.com
Menu
SUPN SUPN Quote SUPN Short SUPN News SUPN Articles SUPN Message Board
Get SUPN Alerts

News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures | Benzinga

ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN | Benzinga

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Su...

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease | Benzinga

On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion...

Supernus to Participate in Two Upcoming Investor Conferences | Benzinga

ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developi...
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference | Benzinga

ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developin...

Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent | Benzinga

ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developin...

Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings | Benzinga

Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the ris...
SVP at Supernus Pharmaceuticals Exercises Options Worth $55K | Benzinga

Frank Mottola, SVP at Supernus Pharmaceuticals (NASDAQ:SUPN), reported a large exercise of company stock options on November 16, according to a new...

Supernus to Participate in the Jefferies London Healthcare Conference | Benzinga

ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developin...

Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023 | Benzinga

ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developin...
Previous 10 Next 10